KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Change in Accured Expenses (2016 - 2025)

Bausch Health Companies' Change in Accured Expenses history spans 17 years, with the latest figure at -$284.0 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 1283.33% year-over-year to -$284.0 million; the TTM value through Dec 2025 reached -$76.0 million, down 121.29%, while the annual FY2025 figure was -$76.0 million, 121.29% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$284.0 million at Bausch Health Companies, down from $144.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $166.0 million in Q3 2023 and bottomed at -$284.0 million in Q4 2025.
  • The 5-year median for Change in Accured Expenses is $48.0 million (2022), against an average of $24.2 million.
  • The largest annual shift saw Change in Accured Expenses soared 737.5% in 2024 before it tumbled 1283.33% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$170.0 million in 2021, then skyrocketed by 127.65% to $47.0 million in 2022, then soared by 106.38% to $97.0 million in 2023, then tumbled by 75.26% to $24.0 million in 2024, then crashed by 1283.33% to -$284.0 million in 2025.
  • Per Business Quant, the three most recent readings for BHC's Change in Accured Expenses are -$284.0 million (Q4 2025), $144.0 million (Q3 2025), and $163.0 million (Q2 2025).